Basic immunohistochemistry for lymphoma diagnosis.

Area of Science:

• Immunopathology
• Molecular Diagnostics
• Oncology

Background:

• Immunohistochemistry (IHC) utilizes antigen-antibody interactions to identify specific cellular proteins.
• Accurate lymphoma diagnosis relies on IHC for cell lineage, maturation stage, genetic alterations, proliferation, and therapeutic targets.

Purpose of the Study:

• To highlight the essential role of immunohistochemistry in lymphoma diagnosis.
• To detail key markers used in lymphoma subtyping and treatment selection.
• To emphasize the importance of proper specimen processing for diagnostic accuracy.

Main Methods:

• Utilizing specific antibodies (e.g., CD3, CD20, CD79a, CD56) to detect cell lineage and differentiation.
• Employing markers like Bcl-2, cyclin D-1, and Ki-67 to identify genetic alterations and proliferation.
• Leveraging IHC for therapeutic target identification (e.g., PD-L1, CD19, CD30).

Main Results:

• CD3 and CD20 serve as crucial pan T-cell and B-cell markers, respectively.
• CD79a offers an alternative to CD20, especially in specific tumor contexts.
• IHC detects genetic alterations (BCL2, CCND1) and proliferation (Ki-67), aiding in lymphoma classification.
• Markers like PD-L1, CD19, and CD30 are identified as key targets for immunotherapy.

Conclusions:

• Immunohistochemistry is indispensable for comprehensive lymphoma diagnosis and classification.
• Accurate interpretation of IHC markers guides therapeutic strategies and patient management.
• Strict adherence to pre-analytical procedures is paramount for reliable IHC results in lymphoma diagnostics.